Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), bought 4,650 shares at $21.44 ($100K) on 2019-05-13, disclosed to the SEC on 2019-05-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| AXSM | SELL | 2026-02-27 | $4.0M | — | Filing → |
| AXSM | BUY | 2025-09-09 | $263K | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |